Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03719898
Title Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Fox Chase Cancer Center
Indications

anaplastic large cell lymphoma

Therapies

Brigatinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST